# Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)

> **NCT03690206** · PHASE3 · COMPLETED · sponsor: **Zealand Pharma** · enrollment: 106 (actual)

## Conditions studied

- Short Bowel Syndrome

## Interventions

- **DRUG:** glepaglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03690206
- **Lead sponsor:** Zealand Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-04
- **Primary completion:** 2022-07-26
- **Final completion:** 2022-07-26
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2025-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03690206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03690206, "Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03690206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*